An Open-label Study of AZD0120 in Adults With Multiple Sclerosis

Part of paid clinical trials in Tucson, Arizona.

Sponsor
AstraZeneca
Study ID
NCT07224373
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 60 Years
Healthy Volunteers
Not accepted

Interventions

  • AZD0120 - Regimen 1 — BIOLOGICAL
    Regimen 1, infusion of AZD0120
  • AZD0120 - Regimen 2 — BIOLOGICAL
    Regimen 2, infusion of AZD0120

Study Details

This trial is a Phase 1b, open-label, multi-center, clinical study of AZD0120, a BCMA/CD19 dual targeting CAR+ T-cell therapy, to evaluate the safety and tolerability in adult participants with Multiple Sclerosis.

Key Dates

Start date
Dec 9, 2025
Status verified
May 2026
Primary completion
Dec 7, 2028
Completion
Dec 7, 2028

Study Design

Enrollment
24 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Arm/Group 1: AZD0120 RMS
    AZD0120 RMS
  • Experimental: Arm/Group 2: AZD0120 PMS
    AZD0120 PMS

Primary Outcome Measure

Evaluate the safety, and tolerability of AZD0120 in participants with MS (disease cohort 1: RMS; disease cohort 2: PMS) [ Time Frame: Day 1 to day 29, and over 104 weeks ]

Central Contacts

Locations (9)

FacilityCityStateZIPSite coordinators
Research SiteTucsonArizona85719-
Research SiteAuroraColorado80045-
Research SiteWashington D.C.District of Columbia20010-
Research SiteSt LouisMissouri63110-
Research SiteNew YorkNew York10016-
Research SiteNew YorkNew York10032-
Research SiteClevelandOhio44195-
Research SiteSeattleWashington98122-
Research SiteMilwaukeeWisconsin53226-

Find similar trials in Tucson, AZ

By condition
Multiple sclerosis
By specialty
NeurologyBrain disordersAutoimmune disease
By research site
Research Site· Tucson, AZResearch Site· Aurora, COResearch Site· Washington D.C., DCResearch Site· St Louis, MOResearch Site· New York, NYResearch Site· Cleveland, OH

Related Studies